Jacob Kimmel

Jacob Kimmel is the co-founder and CEO of NewLimit, a biotechnology company based in South San Francisco that develops epigenetic reprogramming medicines for aging-related diseases. Prior to founding NewLimit in 2022, he served as a principal investigator at Calico Life Sciences, where he led a laboratory focused on epigenetic reprogramming and cell age reversal. He holds a Ph.D. in developmental and stem cell biology from the University of California, San Francisco, and his scientific work combines computational biology, machine learning, and single-cell genomics.